• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by argenx SE

    2/12/24 6:08:26 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARGX alert in real time by email
    SC 13G 1 d758086dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c)

    and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2.

    Under the Securities Exchange Act of 1934

    (Amendment No.  )*

     

     

    Argenx SE

    (Name of Issuer)

    American Depositary Shares

    (Title of Class of Securities)

    04016X101

    (CUSIP Number)

    12/31/2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.   04016X101    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Limited Partnership

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     None

       6  

     SHARED VOTING POWER

     

     2,705,482

       7  

     SOLE DISPOSITIVE POWER

     

     None

       8  

     SHARED DISPOSITIVE POWER

     

     3,174,477

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,174,477

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions) ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.4%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     IA


    CUSIP No.   04016X101    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Investments GP LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     None

       6  

     SHARED VOTING POWER

     

     2,705,482

       7  

     SOLE DISPOSITIVE POWER

     

     None

       8  

     SHARED DISPOSITIVE POWER

     

     3,174,477

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,174,477

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)  ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.4%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC


    CUSIP No.   04016X101    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Holdings LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     None

       6  

     SHARED VOTING POWER

     

     2,705,482

       7  

     SOLE DISPOSITIVE POWER

     

     None

       8  

     SHARED DISPOSITIVE POWER

     

     3,174,477

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,174,477

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)  ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.4%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC


    CUSIP No.   04016X101    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Asset Management Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     None

       6  

     SHARED VOTING POWER

     

     2,705,482

       7  

     SOLE DISPOSITIVE POWER

     

     None

       8  

     SHARED DISPOSITIVE POWER

     

     3,174,477

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,174,477

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions) ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.4%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC


    Item 1(a)

    Name of Issuer:

    Argenx SE

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands

     

    Item 2(a)

    Name of Person Filing:

    Artisan Partners Limited Partnership (“APLP”)

    Artisan Investments GP LLC (“Artisan Investments”)

    Artisan Partners Holdings LP (“Artisan Holdings”)

    Artisan Partners Asset Management Inc. (“APAM”)

     

    Item 2(b)

    Address of Principal Business Office:

    APLP, Artisan Investments, Artisan Holdings, and APAM are all located at:

    875 East Wisconsin Avenue, Suite 800

    Milwaukee, WI 53202

     

    Item 2(c)

    Citizenship:

    APLP is a Delaware limited partnership

    Artisan Investments is a Delaware limited liability company

    Artisan Holdings is a Delaware limited partnership

    APAM is a Delaware corporation

     

    Item 2(d)

    Title of Class of Securities:

    American Depositary Shares

     

    Item 2(e)

    CUSIP Number:

    04016X101

     

    Item 3

    Type of Person:

    (e) APLP is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

    (g) Artisan Holdings is the sole limited partner of APLP and the sole member of Artisan Investments; Artisan Investments is the general partner of APLP; APAM is the general partner of Artisan Holdings.


    Item 4

    Ownership (at 12/31/2023):

     

      (a)

    Amount owned “beneficially” within the meaning of rule 13d-3:

    3,174,477

     

      (b)

    Percent of class:

    5.4% (based on 59,194,488 shares outstanding as of 1/4/2024)

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or to direct the vote: None

     

      (ii)

    shared power to vote or to direct the vote: 2,705,482

     

      (iii)

    sole power to dispose or to direct the disposition of: None

     

      (iv)

    shared power to dispose or to direct the disposition of: 3,174,477

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not Applicable

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The shares reported herein have been acquired on behalf of discretionary clients of APLP. Persons other than APLP are entitled to receive all dividends from, and proceeds from the sale of, those shares. None of those persons, to the knowledge of APLP, Artisan Holdings, APAM, or Artisan Investments has an economic interest in more than 5% of the class.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

     

    Item 8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    Item 9

    Notice of Dissolution of Group:

    Not Applicable

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: 2/12/2024

     

    ARTISAN PARTNERS ASSET MANAGEMENT INC,

    for itself and as the general partner of

    ARTISAN PARTNERS HOLDINGS LP
    By:  

    Gregory K. Ramirez *

    ARTISAN INVESTMENTS GP LLC,

    for itself and as the general partner of

    ARTISAN PARTNERS LIMITED PARTNERSHIP
    By:  

    Gregory K. Ramirez *

    *By:  

    /s/ Gregory K. Ramirez

      Gregory K. Ramirez
      Executive Vice President of Artisan Partners Asset Management Inc.
      Vice President of Artisan Investments GP LLC


    Exhibit Index

     

    Exhibit 1    Joint Filing Agreement dated 2/12/2024 by and among Artisan Partners Limited Partnership, Artisan Investments GP LLC, Artisan Partners Holdings LP, and Artisan Partners Asset Management Inc.
    Get the next $ARGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARGX

    DatePrice TargetRatingAnalyst
    3/10/2026Hold → Buy
    Deutsche Bank
    12/18/2025$858.00Outperform → Neutral
    Robert W. Baird
    11/24/2025Outperform → Peer Perform
    Wolfe Research
    9/15/2025$918.00Buy
    Truist
    9/11/2025Buy → Hold
    Deutsche Bank
    8/25/2025$850.00Outperform
    RBC Capital Mkts
    7/8/2025Hold → Buy
    Deutsche Bank
    7/3/2025$700.00Overweight
    Morgan Stanley
    More analyst ratings

    $ARGX
    SEC Filings

    View All

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    3/20/26 4:24:11 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 20-F filed by argenx SE

    20-F - ARGENX SE (0001697862) (Filer)

    3/19/26 6:13:02 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    3/19/26 6:05:34 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    argenx announces Annual General Meeting of Shareholders on May 6, 2026

    March 20, 2026 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting a

    3/20/26 4:01:00 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

    Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypesNew biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-f

    3/6/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative ("seronegative") gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported f

    2/26/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    argenx upgraded by Deutsche Bank

    Deutsche Bank upgraded argenx from Hold to Buy

    3/10/26 3:28:52 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded argenx from Outperform to Neutral and set a new price target of $858.00

    12/18/25 8:54:11 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx downgraded by Wolfe Research

    Wolfe Research downgraded argenx from Outperform to Peer Perform

    11/24/25 8:14:37 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    Financials

    Live finance-specific insights

    View All

    argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative ("seronegative") gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported f

    2/26/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

    February 19, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium           32 800 50

    2/19/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

    $1.13 billion in third quarter global product net sales  On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2025 financial results and provided a business update. "argenx continues to deliver on

    10/30/25 2:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by argenx SE

    SC 13G/A - ARGENX SE (0001697862) (Subject)

    11/14/24 1:22:37 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by argenx SE

    SC 13G/A - ARGENX SE (0001697862) (Subject)

    11/12/24 9:50:11 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by argenx SE (Amendment)

    SC 13G/A - ARGENX SE (0001697862) (Subject)

    2/14/24 10:03:02 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    Leadership Updates

    Live Leadership Updates

    View All

    argenx announces Annual General Meeting of Shareholders on May 6, 2026

    March 20, 2026 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting a

    3/20/26 4:01:00 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx Announces Leadership Transition Marking Next Evolution of Growth

    Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, current Chief Operating Officer, will transition to Chief Executive Officer and Executive Director and Tim Van Hauwermeiren, current Chief Executive Officer, will transition to non-Executive Director and Chairman of the Board of Directors. Tim will succeed Peter Verhaeghe, w

    1/5/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

    January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f

    1/16/23 1:30:00 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care